Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | — |
| Operating income | -$19.6M | -$39.8M | -$53.8M | -$36.9M | -$54.4M | -$63.0M |
| Net income | -$19.5M | -$39.8M | -$52.0M | -$35.3M | -$52.7M | -$59.5M |
| EPS (diluted) | -$9.60 | -$2.19 | -$2.12 | -$124.41 | -$15.28 | -$4.40 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$18.5M | -$38.0M | -$47.4M | -$34.5M | -$51.1M | -$51.8M |
| Capital expenditures | $24.0K | $198K | $346K | $246K | $52.0K | $46.0K |
| Free cash flow | -$18.6M | -$38.2M | -$47.7M | -$34.8M | -$51.2M | -$51.9M |
| Share buybacks | — | — | — | $4.40M | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $53.6M | $125M | $19.9M | $29.9M | $111M | $59.0M |
| Total assets | $55.2M | $154M | $108M | $35.7M | $115M | $62.1M |
| Total liabilities | $4.62M | $6.81M | $8.21M | $7.75M | $11.1M | $5.93M |
| Shareholders' equity | -$42.1M | $147M | -$54.4M | -$102M | $104M | $56.2M |
| Retained earnings | -$45.0M | -$84.7M | -$137M | -$102M | -$155M | -$214M |
| Shares (wtd avg diluted) | 2.03M | 18.1M | 24.5M | 284K | 3.45M | 13.5M |
Every figure is extracted from OnKure Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.